Recombinant antibody production leverages mammalian cell lines for the generation of therapeutic antibodies. Chinese hamster ovary (CHO) cells rose as a leading platform due to their capability in producing complex, humanized antibodies. High-yield cultivation of CHO cells is crucial for commercial success and involves meticulous optimization of va